Posted inBiotechnology
Posted inBiotechnology
Neumora stumbles at start of phase 3 depression readout run, sending stock down 80%
Neumora Therapeutics’ big bet on a new era of neuroscience has delivered an age-old result. The first of three late-stage…




















